Global Biosimilars Market Synopsis

Global Biosimilars Market Size Was Valued at USD 36 Billion in 2022, and is Projected to Reach USD 102.69 Billion by 2030, Growing at a CAGR of 14% From 2023-2030.

Biosimilars are biologic medical products that are highly similar to an already approved biological medicine, known as the reference product or originator. They are designed to have no clinically meaningful differences in terms of safety, efficacy, and quality compared to the reference product. Unlike generic versions of small molecule drugs, which are exact copies of their original counterparts, biosimilars are not identical but are highly similar in structure, function, and efficacy.

  • The global biosimilars market has been experiencing substantial growth driven by the rising demand for cost-effective alternatives to expensive biologic drugs. With patents expiring on several blockbuster biologics, the market for biosimilars has expanded, offering opportunities for increased access to critical treatments across various therapeutic areas. Regions like North America, Europe, and Asia-Pacific have witnessed significant advancements in biosimilar development and adoption, driven by favourable regulatory frameworks and efforts to contain healthcare costs.
  • Companies operating in the biosimilars market are focusing on expanding their portfolios and improving manufacturing capabilities to meet the growing demand. Regulatory agencies' streamlined approval processes have encouraged market players to invest in research and development, leading to an influx of new biosimilar products. Moreover, healthcare systems worldwide are increasingly embracing biosimilars to alleviate the financial burden associated with expensive biologics, fostering market growth and accessibility for patients in need of these treatments.

Biosimilars Market

Global Biosimilars Market Trend Analysis

Launch of Novel Biosimilars

  • The emergence and launch of novel biosimilars are catalysing a substantial transformation within the Global Biosimilars Market. These new, highly comparable versions of existing biologic drugs offer a cost-effective alternative to their originator counterparts, fostering increased accessibility to essential treatments. Their arrival introduces competitive dynamics, providing healthcare systems and patients with expanded choices while driving down the overall expenditure on biologic therapies.
  • The ongoing launch of novel biosimilars not only addresses the growing demand for advanced treatment options but also stimulates market competition, paving the way for enhanced affordability and wider patient access to life-saving medications. With the expiration of patents on several blockbuster biologics, pharmaceutical companies are actively seizing this opportunity to develop and introduce biosimilars, fostering a more competitive landscape and a shift toward value-based healthcare.
  • This trend is poised to significantly impact the global biosimilars market, fueling its growth trajectory in the coming years. As regulatory pathways become more established and confidence in biosimilar efficacy and safety grows, the market is expected to witness a surge in novel biosimilar launches, driving increased adoption rates and reshaping the therapeutic landscape across various medical domains

Emerging markets

  • These markets, often characterized by expanding healthcare infrastructure and an increasing demand for affordable treatments, offer a fertile ground for biosimilar products. Countries in regions like Asia-Pacific, Latin America, and parts of Eastern Europe are witnessing a rising prevalence of chronic diseases and a growing aging population. This demographic shift propels the demand for cost-effective treatment options, making biosimilars a compelling solution to address these healthcare challenges.
  • Regulatory reforms in many emerging economies are streamlining the approval processes for biosimilars, facilitating quicker market entry. This favourable regulatory environment encourages pharmaceutical companies to invest in the development and commercialization of biosimilar drugs, further fueling market expansion. Additionally, partnerships and collaborations between local and global biopharmaceutical firms are fostering innovation and enabling greater accessibility of biosimilar medicines in these regions.

Global Biosimilars Market Segment Analysis:

Global Biosimilars Market Segmented on the basis of type, application, and end-users.

By Product Class, Monoclonal antibodies segment is expected to dominate the market during the forecast period

  • Monoclonal antibodies offer versatility in treating a wide array of diseases, including cancer, autoimmune disorders, infectious diseases, and more. Their targeted approach towards specific molecules or cells within the body allows for precise and effective treatment, leading to their increased adoption across therapeutic areas. Many originator monoclonal antibodies have demonstrated significant clinical success and efficacy in treating various conditions. Biosimilar versions of these antibodies aim to replicate the therapeutic effects of the original drugs, often at a reduced cost. This similarity in efficacy, coupled with potential cost savings, makes them an attractive option for healthcare providers and patients.
  • Several blockbuster monoclonal antibody drugs have faced or are approaching patent expirations, creating substantial market opportunities for biosimilar manufacturers.

By Application, Oncology segment held the largest share of 33% in 2022

  • There's a consistently high demand for effective treatments in oncology. Biosimilar versions of monoclonal antibodies used in cancer treatment have gained traction due to their potential to offer cost-effective alternatives to expensive originator biologics, widening accessibility for patients in need.
  • Many originator biologics used in cancer treatment are costly. Biosimilar alternatives offer the promise of similar efficacy and safety profiles at reduced costs, making them an attractive option for healthcare providers and systems aiming to manage the financial burden associated with cancer care.
  • Several blockbuster oncology biologics have faced or were approaching patent expirations, leading to the entry of biosimilar versions into the market. This has created opportunities for biosimilar manufacturers to penetrate the oncology segment and offer competitive alternatives.

Global Biosimilars Market Regional Insights:

Europe is Expected to Dominate the Market Over the Forecast period

  • Germany has been a frontrunner in the European biosimilars market. Its healthcare system encourages the use of biosimilars through various policies, tenders, and pricing strategies. With a robust regulatory framework and a strong emphasis on cost containment, Germany has been a major adopter of biosimilars across therapeutic areas.
  • The UK has also played a pivotal role in driving biosimilar adoption. Initiatives from the National Health Service (NHS) and various healthcare bodies have promoted the utilization of biosimilars, particularly in oncology and autoimmune diseases.

Global Biosimilars Market Top Key Players:

  • Pfizer, Inc. (US)
  • Amgen, Inc. (US)
  • Eli Lilly and Company (US)
  • Coherus Biosciences, Inc. (US)
  • Merck & Co., Inc. (US)
  • AbbVie Inc. (US)
  • Biogen Inc. (US)
  • Epirus Biopharmaceuticals (US)
  • Apotex Inc. (Canada)
  • Mylan N.V. (Netherlands)
  • Alvotech (Europe)
  • Boehringer Ingelheim International GmbH (Germany)
  • Fresenius Kabi AG(Germany)
  • Formycon AG (Germany)
  • STADA Arzneimittel AG(Germany)
  • Novartis ag (Switzerland)
  • Samsung Bioepis Co., Ltd (South Korea)
  • Celltrion Inc. (South Korea)
  • Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Intas Pharmaceuticals Ltd. (India)
  • Biocon (India)
  • Bio-Thera Solutions (China)
  • Eli Lilly and Company (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)

Key Industry Developments in the Global Biosimilars Market:

  • In May 2023, Boehringer Ingelheim received U.S. FDA clearance for Cyltezo Pen, a novel autoinjector choice for Cyltezo (adalimumab-adbm), an FDA-approved interchangeable biosimilar to Humira.
  • In June 2022, Biogen Inc. partnered with Samsung Bioepis Co., Ltd. to introduce BYOOVIZ (ranibizumab-nuna), a biosimilar of LUCENTIS (ranibizumab) in the U.S

Global Biosimilars Market

Base Year:

2022

Forecast Period:

2023-2030

 

Historical Data:

2017 to 2022

Market Size in 2022:

USD 36 Bn.

 

CAGR (2023-2030) :

14%

Market Size in 2030:

USD 102.69 Bn.

 

Segments Covered:

By Product Class

  • Monoclonal Antibodies
  • Recombinant Hormones
  • Immunomodulators
  • Anti-inflammatory Agents

 

By Application

  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  •  Oncology

 

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

 

Key Market Drivers:

  • Launch of novel biosimilars

Key Market Restraints:

  • Complexities in Manufacturing

Key Opportunities:

  • Emerging markets

Companies Covered in the Report:

  • Pfizer, Inc., Amgen, Inc, Eli Lilly and Company, Coherus Biosciences, Inc, Merck & Co., Inc and Other Major Players.
  1. INTRODUCTION
    1. RESEARCH OBJECTIVES
    2. RESEARCH METHODOLOGY
    3. RESEARCH PROCESS
    4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
    5. MARKET SEGMENTATION
  2. EXECUTIVE SUMMARY
  3. MARKET OVERVIEW
  4. GROWTH OPPORTUNITIES BY SEGMENT
  5. MARKET LANDSCAPE
    1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
    2. INDUSTRY VALUE CHAIN ANALYSIS
    3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
    4. MARKET TREND ANALYSIS
    5. REGULATORY LANDSCAPE
    6. PESTLE ANALYSIS
    7. PRICE TREND ANALYSIS
    8. PATENT ANALYSIS
    9. TECHNOLOGY EVALUATION
    10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
      1. Geopolitical Market Disruptions
      2. Supply Chain Disruptions
      3. Instability in Emerging Markets
    11. ECOSYSTEM
  6. BIOSIMILARS MARKET BY PRODUCT CLASS (2016-2030)
    1. BIOSIMILARS MARKET SNAPSHOT AND GROWTH ENGINE
    2. MARKET OVERVIEW
    3. MONOCLONAL ANTIBODIES
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
    4. RECOMBINANT HORMONES
    5. IMMUNOMODULATORS
    6. ANTI-INFLAMMATORY AGENTS
  7. BIOSIMILARS MARKET BY APPLICATION (2016-2030)
    1. BIOSIMILARS MARKET SNAPSHOT AND GROWTH ENGINE
    2. MARKET OVERVIEW
    3. BLOOD DISORDERS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
    4. GROWTH HORMONAL DEFICIENCY
    5. CHRONIC AND AUTOIMMUNE DISORDERS
    6. ONCOLOGY
  8. COMPANY PROFILES AND COMPETITIVE ANALYSIS
    1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. BIOSIMILARS Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
    2. PFIZER, INC
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
    3. Amgen, Inc.
    4. Eli Lilly and Company
    5. Coherus Biosciences, Inc.
    6. Merck & Co., Inc.
    7. AbbVie Inc.
    8. Biogen Inc.
    9. Epirus Biopharmaceuticals
    10. Apotex Inc.
    11. Mylan N.V.
    12. Alvotech
    13. Boehringer Ingelheim International GmbH
    14. Fresenius Kabi AG
    15. Formycon AG
    16. STADA Arzneimittel AG
    17. Novartis AG
    18. Samsung Bioepis Co., Ltd
    19. Celltrion Inc.
    20. Fujifilm Kyowa Kirin Biologics Co., Ltd.
  9. GLOBAL BIOSIMILARS MARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Product Class
      4. Historic And Forecasted Market Size By Application
      5. Historic And Forecasted Market Size By Country
        1. USA
        2. Canada
        3. Mexico
    3. EASTERN EUROPE
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
        1. Russia
        2. Bulgaria
        3. The Czech Republic
        4. Hungary
        5. Poland
        6. Romania
        7. Rest Of Eastern Europe
    4. WESTERN EUROPE
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
        1. Germany
        2. United Kingdom
        3. France
        4. The Netherlands
        5. Italy
        6. Spain
        7. Rest Of Western Europe
    5. ASIA PACIFIC
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
        1. China
        2. India
        3. Japan
        4. South Korea
        5. Malaysia
        6. Thailand
        7. Vietnam
        8. The Philippines
        9. Australia
        10. New-Zealand
        11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
        1. Turkey
        2. Bahrain
        3. Kuwait
        4. Saudi Arabia
        5. Qatar
        6. UAE
        7. Israel
        8. South Africa
    7. SOUTH AMERICA
      1. Key Market Trends, Growth Factors And Opportunities
      2. Key Manufacturers
      3. Historic And Forecasted Market Size By Segments
      4. Historic And Forecasted Market Size By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
  10. INVESTMENT ANALYSIS
  11. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

Global Biosimilars Market

Base Year:

2022

Forecast Period:

2023-2030

 

Historical Data:

2017 to 2022

Market Size in 2022:

USD 36 Bn.

 

CAGR (2023-2030) :

14%

Market Size in 2030:

USD 102.69 Bn.

 

Segments Covered:

By Product Class

  • Monoclonal Antibodies
  • Recombinant Hormones
  • Immunomodulators
  • Anti-inflammatory Agents

 

By Application

  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic and Autoimmune Disorders
  •  Oncology

 

By Region

  • North America (U.S., Canada, Mexico)
  • Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
  • Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
  • Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
  • Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
  • South America (Brazil, Argentina, Rest of SA)

 

Key Market Drivers:

  • Launch of novel biosimilars

Key Market Restraints:

  • Complexities in Manufacturing

Key Opportunities:

  • Emerging markets

Companies Covered in the Report:

  • Pfizer, Inc., Amgen, Inc, Eli Lilly and Company, Coherus Biosciences, Inc, Merck & Co., Inc and Other Major Players.

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOSIMILARS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOSIMILARS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOSIMILARS MARKET COMPETITIVE RIVALRY
TABLE 005. BIOSIMILARS MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOSIMILARS MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOSIMILARS MARKET BY TYPE
TABLE 008. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    
     HUMAN GROWTH HORMONES
     GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)
     INTERFERONS
     INSULIN
    
     (HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
TABLE 009. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
TABLE 010. INTERFERONS MARKET OVERVIEW (2016-2028)
TABLE 011. INSULIN) MARKET OVERVIEW (2016-2028)
TABLE 012. HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
TABLE 013. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
TABLE 014. INTERFERONS MARKET OVERVIEW (2016-2028)
TABLE 015. INSULIN MARKET OVERVIEW (2016-2028)
TABLE 016. RECOMBINANT GLYCOSYLATED PROTEINS
    
     ERYTHROPOIETIN
     MONOCLONAL ANTIBODIES
     FOLLITROPIN
    
     (ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
TABLE 017. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
TABLE 018. FOLLITROPIN) MARKET OVERVIEW (2016-2028)
TABLE 019. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
TABLE 020. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
TABLE 021. FOLLITROPIN MARKET OVERVIEW (2016-2028)
TABLE 022. BIOSIMILARS MARKET BY APPLICATION
TABLE 023. BLOOD DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 024. GROWTH HORMONAL DEFICIENCY MARKET OVERVIEW (2016-2028)
TABLE 025. CHRONIC AND AUTOIMMUNE DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 026. ONCOLOGY MARKET OVERVIEW (2016-2028)
TABLE 027. AND OTHER APPLICATIONS MARKET OVERVIEW (2016-2028)
TABLE 028. NORTH AMERICA BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 029. NORTH AMERICA BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 030. N BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 031. EUROPE BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 032. EUROPE BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 033. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 034. ASIA PACIFIC BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 035. ASIA PACIFIC BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 036. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 038. MIDDLE EAST & AFRICA BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 039. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 040. SOUTH AMERICA BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 041. SOUTH AMERICA BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 042. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 043. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 044. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 045. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 046. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. PFIZER INC. (US): SNAPSHOT
TABLE 047. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 048. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 049. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. DR. REDDY’S LABORATORIES LTD. (INDIA): SNAPSHOT
TABLE 050. DR. REDDY’S LABORATORIES LTD. (INDIA): BUSINESS PERFORMANCE
TABLE 051. DR. REDDY’S LABORATORIES LTD. (INDIA): PRODUCT PORTFOLIO
TABLE 052. DR. REDDY’S LABORATORIES LTD. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. AMGEN INC. (US): SNAPSHOT
TABLE 053. AMGEN INC. (US): BUSINESS PERFORMANCE
TABLE 054. AMGEN INC. (US): PRODUCT PORTFOLIO
TABLE 055. AMGEN INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. ELI LILLY AND COMPANY (US): SNAPSHOT
TABLE 056. ELI LILLY AND COMPANY (US): BUSINESS PERFORMANCE
TABLE 057. ELI LILLY AND COMPANY (US): PRODUCT PORTFOLIO
TABLE 058. ELI LILLY AND COMPANY (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): SNAPSHOT
TABLE 059. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): BUSINESS PERFORMANCE
TABLE 060. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): PRODUCT PORTFOLIO
TABLE 061. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. FRESENIUS SE & CO. KGAA (GERMANY): SNAPSHOT
TABLE 062. FRESENIUS SE & CO. KGAA (GERMANY): BUSINESS PERFORMANCE
TABLE 063. FRESENIUS SE & CO. KGAA (GERMANY): PRODUCT PORTFOLIO
TABLE 064. FRESENIUS SE & CO. KGAA (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. STADA ARZNEIMITTEL AG (GERMANY): SNAPSHOT
TABLE 065. STADA ARZNEIMITTEL AG (GERMANY): BUSINESS PERFORMANCE
TABLE 066. STADA ARZNEIMITTEL AG (GERMANY): PRODUCT PORTFOLIO
TABLE 067. STADA ARZNEIMITTEL AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. BOEHRINGER INGELHEIM (GERMANY): SNAPSHOT
TABLE 068. BOEHRINGER INGELHEIM (GERMANY): BUSINESS PERFORMANCE
TABLE 069. BOEHRINGER INGELHEIM (GERMANY): PRODUCT PORTFOLIO
TABLE 070. BOEHRINGER INGELHEIM (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. GEDEON RICHTER PLC (HUNGARY): SNAPSHOT
TABLE 071. GEDEON RICHTER PLC (HUNGARY): BUSINESS PERFORMANCE
TABLE 072. GEDEON RICHTER PLC (HUNGARY): PRODUCT PORTFOLIO
TABLE 073. GEDEON RICHTER PLC (HUNGARY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. CELLTRION (SOUTH KOREA): SNAPSHOT
TABLE 074. CELLTRION (SOUTH KOREA): BUSINESS PERFORMANCE
TABLE 075. CELLTRION (SOUTH KOREA): PRODUCT PORTFOLIO
TABLE 076. CELLTRION (SOUTH KOREA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. SAMSUNG BIOLOGICS (SOUTH KOREA): SNAPSHOT
TABLE 077. SAMSUNG BIOLOGICS (SOUTH KOREA): BUSINESS PERFORMANCE
TABLE 078. SAMSUNG BIOLOGICS (SOUTH KOREA): PRODUCT PORTFOLIO
TABLE 079. SAMSUNG BIOLOGICS (SOUTH KOREA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. COHERUS BIOSCIENCES (US): SNAPSHOT
TABLE 080. COHERUS BIOSCIENCES (US): BUSINESS PERFORMANCE
TABLE 081. COHERUS BIOSCIENCES (US): PRODUCT PORTFOLIO
TABLE 082. COHERUS BIOSCIENCES (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. BIOCON LIMITED (INDIA): SNAPSHOT
TABLE 083. BIOCON LIMITED (INDIA): BUSINESS PERFORMANCE
TABLE 084. BIOCON LIMITED (INDIA): PRODUCT PORTFOLIO
TABLE 085. BIOCON LIMITED (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. VIATRIS INC. (US): SNAPSHOT
TABLE 086. VIATRIS INC. (US): BUSINESS PERFORMANCE
TABLE 087. VIATRIS INC. (US): PRODUCT PORTFOLIO
TABLE 088. VIATRIS INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. AMEGA BIOTECH (ARGENTINA): SNAPSHOT
TABLE 089. AMEGA BIOTECH (ARGENTINA): BUSINESS PERFORMANCE
TABLE 090. AMEGA BIOTECH (ARGENTINA): PRODUCT PORTFOLIO
TABLE 091. AMEGA BIOTECH (ARGENTINA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 091. APOTEX INC. (CANADA): SNAPSHOT
TABLE 092. APOTEX INC. (CANADA): BUSINESS PERFORMANCE
TABLE 093. APOTEX INC. (CANADA): PRODUCT PORTFOLIO
TABLE 094. APOTEX INC. (CANADA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 094. BIOCAD (RUSSIA): SNAPSHOT
TABLE 095. BIOCAD (RUSSIA): BUSINESS PERFORMANCE
TABLE 096. BIOCAD (RUSSIA): PRODUCT PORTFOLIO
TABLE 097. BIOCAD (RUSSIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 097. MABXIENCE (SPAIN): SNAPSHOT
TABLE 098. MABXIENCE (SPAIN): BUSINESS PERFORMANCE
TABLE 099. MABXIENCE (SPAIN): PRODUCT PORTFOLIO
TABLE 100. MABXIENCE (SPAIN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100. PROBIOMED S.A. DE C.V. (MEXICO): SNAPSHOT
TABLE 101. PROBIOMED S.A. DE C.V. (MEXICO): BUSINESS PERFORMANCE
TABLE 102. PROBIOMED S.A. DE C.V. (MEXICO): PRODUCT PORTFOLIO
TABLE 103. PROBIOMED S.A. DE C.V. (MEXICO): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): SNAPSHOT
TABLE 104. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): BUSINESS PERFORMANCE
TABLE 105. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): PRODUCT PORTFOLIO
TABLE 106. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106. INTAS PHARMACEUTICALS LTD. (INDIA): SNAPSHOT
TABLE 107. INTAS PHARMACEUTICALS LTD. (INDIA): BUSINESS PERFORMANCE
TABLE 108. INTAS PHARMACEUTICALS LTD. (INDIA): PRODUCT PORTFOLIO
TABLE 109. INTAS PHARMACEUTICALS LTD. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. THERMEX (UK): SNAPSHOT
TABLE 110. THERMEX (UK): BUSINESS PERFORMANCE
TABLE 111. THERMEX (UK): PRODUCT PORTFOLIO
TABLE 112. THERMEX (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. RELIANCE LIFE SCIENCES (INDIA): SNAPSHOT
TABLE 113. RELIANCE LIFE SCIENCES (INDIA): BUSINESS PERFORMANCE
TABLE 114. RELIANCE LIFE SCIENCES (INDIA): PRODUCT PORTFOLIO
TABLE 115. RELIANCE LIFE SCIENCES (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. KASHIV BIOSCIENCES (US): SNAPSHOT
TABLE 116. KASHIV BIOSCIENCES (US): BUSINESS PERFORMANCE
TABLE 117. KASHIV BIOSCIENCES (US): PRODUCT PORTFOLIO
TABLE 118. KASHIV BIOSCIENCES (US): KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOSIMILARS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOSIMILARS MARKET OVERVIEW BY TYPE
FIGURE 012. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    
     HUMAN GROWTH HORMONES
     GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)
     INTERFERONS
     INSULIN
    
     (HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
FIGURE 013. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
FIGURE 014. INTERFERONS MARKET OVERVIEW (2016-2028)
FIGURE 015. INSULIN) MARKET OVERVIEW (2016-2028)
FIGURE 016. HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
FIGURE 017. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
FIGURE 018. INTERFERONS MARKET OVERVIEW (2016-2028)
FIGURE 019. INSULIN MARKET OVERVIEW (2016-2028)
FIGURE 020. RECOMBINANT GLYCOSYLATED PROTEINS
    
     ERYTHROPOIETIN
     MONOCLONAL ANTIBODIES
     FOLLITROPIN
    
     (ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
FIGURE 021. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
FIGURE 022. FOLLITROPIN) MARKET OVERVIEW (2016-2028)
FIGURE 023. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
FIGURE 024. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
FIGURE 025. FOLLITROPIN MARKET OVERVIEW (2016-2028)
FIGURE 026. BIOSIMILARS MARKET OVERVIEW BY APPLICATION
FIGURE 027. BLOOD DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 028. GROWTH HORMONAL DEFICIENCY MARKET OVERVIEW (2016-2028)
FIGURE 029. CHRONIC AND AUTOIMMUNE DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 030. ONCOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 031. AND OTHER APPLICATIONS MARKET OVERVIEW (2016-2028)
FIGURE 032. NORTH AMERICA BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. EUROPE BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 034. ASIA PACIFIC BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 035. MIDDLE EAST & AFRICA BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 036. SOUTH AMERICA BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)

Please Wait...

Frequently Asked Questions :

What would be the forecast period in the Global Biosimilars Market research report?

The forecast period in the Global Biosimilars Market research report is 2023-2030.

Who are the key players in the Global Biosimilars Market?

Pfizer, Inc.(US),Amgen, Inc. (US),Eli Lilly and Company (US),Coherus Biosciences, Inc. (US),Merck & Co., Inc. (US),AbbVie Inc. (US),Biogen Inc. (US),Epirus Biopharmaceuticals (US),Apotex Inc. (Canada),Mylan N.V. (Netherlands),Alvotech (Europe),Boehringer Ingelheim International GmbH (Germany),Fresenius Kabi AG(Germany),Formycon AG (Germany),STADA Arzneimittel AG(Germany),Novartis ag (Switzerland),Samsung Bioepis Co., Ltd (South Korea),Celltrion Inc. (South Korea),Fujifilm Kyowa Kirin Biologics Co., Ltd. (Japan),Dr. Reddy's Laboratories Ltd. (India),Intas Pharmaceuticals Ltd. (India),Biocon (India),Bio-Thera Solutions (China),Eli Lilly and Company (India),Teva Pharmaceutical Industries Ltd. (Israel) and Other Major Players.

What are the segments of the Global Biosimilars Market?

The Global Biosimilars Market is segmented into Product Class Nature, Application, and region. By Product Class, the market is categorized into Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents By Application, the market is categorized into Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).

What is the Global Biosimilars Market?

Biosimilars are biologic medical products that are highly similar to an already approved biological medicine, known as the reference product or originator. They are designed to have no clinically meaningful differences in terms of safety, efficacy, and quality compared to the reference product. Unlike generic versions of small molecule drugs, which are exact copies of their original counterparts, biosimilars are not identical but are highly similar in structure, function, and efficacy.

How big is the Global Biosimilars Market?

Global Biosimilars Market Size Was Valued at USD 36 Billion in 2022, and is Projected to Reach USD 102.69 Billion by 2030, Growing at a CAGR of 14% From 2023-2030.